Prosecution Insights
Last updated: April 19, 2026
Application No. 18/017,662

ORGANIC TRIAZINE CONTAINING MOLECULES FOR USE IN OPTOELECTRONIC DEVICES

Non-Final OA §103§112
Filed
Jan 23, 2023
Examiner
NGUYEN, VU ANH
Art Unit
1762
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Samsung Display Co., Ltd.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
99%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
1247 granted / 1498 resolved
+18.2% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
31 currently pending
Career history
1529
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
29.2%
-10.8% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1498 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to under 37 C.F.R. 1.84(u)(1) because “[were only a single view is used in an application to illustrate the claimed invention, it must not be numbered and the abbreviation "FIG." must not appear.” Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 3 is objected to because of the following informalities: a comma is missing before “R1”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites the limitation "Rb" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Perhaps claim 8 should be amended to depend on claim 6 or 7. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-2 and 4-17 are rejected under 35 U.S.C. 103 as being unpatentable over US 2020/0235308 A1 to Daniel Zink. Regarding claim 1, Zink discloses a similar compound, differing only in the positions of -CN and the group of formula II on the lower ring of formula I: PNG media_image1.png 284 162 media_image1.png Greyscale Claim 1 Zink One of RT and RV is CN and the other is One of RT and RV is CN and the other is the group of formula II. RI; one of RY and RX is the group of formula II, wherein RI can be an aryl. In other words, in the claimed compound, CN (or CF3) and the group of formula II are adjacent to each other at the ortho and meta positions whereas, in the prior art compound, they are not. However, Zink does not teach away from having CN and the group of formula II adjacent to each other at RT and RV. In fact, as one of RT and RV is CN and the other is RI which can be a C6 aryl wherein the term aryl “may be understood in the broadest sense as any mono-, bi- or polycyclic aromatic moieties” (see [0325]), the scope of RI apparently includes the group of formula II, which is itself a polycyclic aromatic moiety, and the scope of the prior art compound encompasses the claimed compound. Thus, while a compound in which one of RT and RV is CN and the other is RI = formula II is not provided as an example, it would have been obvious to a person of ordinary skill in the art at the time the instant invention was filed to make and use such a compound without expecting any difficulty or negative consequences. Claim 1 is therefore unpatentable for being obvious. See MPEP § 2143 (I)(A) & (B). The features of claim 2 are disclosed at [0010], those of claim 4 at [0054]+, and those of claims 5-8 on pages 4-6. Claim 9 is obvious in view of the rejection of claim 1 and the synthesis method of, e.g., paragraph [0451]. The features of claims 10-17 are disclosed on pages 22-26. Allowable Subject Matter Claim 3 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: In the compound disclosed by Zink, one of RX, RY and RZ must be the group of formula II whereas, in the claimed compound, each of RX, RY and RZ is RI as defined in claim 3. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to VU ANH NGUYEN whose telephone number is (571)270-5454. The examiner can normally be reached M-F 8:00 AM-5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ROBERT JONES can be reached at (571) 270-7733. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VU A NGUYEN/ Primary Examiner, Art Unit 1762
Read full office action

Prosecution Timeline

Jan 23, 2023
Application Filed
Mar 03, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12604662
LIGHT-EMITTING DEVICE AND LIGHT-EMITTING APPARATUS
2y 5m to grant Granted Apr 14, 2026
Patent 12600885
COMPOSITION INCLUDING MONOMER WITH A CARBOXYLIC ACID GROUP, MONOMER WITH A HYDROXYL GROUP, AN ALKYL MONOMER, AND CROSSLINKER AND RELATED ARTICLE AND METHOD
2y 5m to grant Granted Apr 14, 2026
Patent 12598907
ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12598859
LIGHT EMITTING DEVICE AND LIGHT EMITTING DISPLAY DEVICE INCLUDING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12583843
ORGANIC LIGHT-EMITTING DEVICE, METHOD FOR MANUFACTURING SAME, AND COMPOSITION FOR ORGANIC MATERIAL LAYER OF ORGANIC LIGHT-EMITTING DEVICE
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
99%
With Interview (+15.9%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1498 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month